Home › Companies › GRCE

Grace Therapeutics, Inc.

GRCE Rare disease Lead: Phase 3 4 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2025-06-15

Pipeline (3 active programs)

nimodipine

GTx-104

Aneurysmal Subarachnoid Hemorrhage Phase 3 intravenous

betamethasone

GTx-102

Ataxia Telangiectasia Phase 1 oral

bupivacaine

GTx-101

Postherpetic Neuralgia Phase 1 topical

Biotech Distilled coverage (4)

2026-04-28 UPDATE: Grace Therapeutics (GRCE) - The CRL Autopsy and the Smart Money Exit 🔒 Paid
2026-04-24 UPDATE: Grace Therapeutics (GRCE) - The Silent Killer Strikes: Grace Gets a CRL 🔒 Paid
2026-02-14 UPDATE: Grace Therapeutics (GRCE) – The Float Shrinks as the Smart Money Parks for PDUFA 🔒 Paid
2026-01-26 Grace Therapeutics (GRCE): Scientific Deep Dive for GTx-104 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.